Investigational new drugs: FDA's expanded access program : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Investigational new drugs: FDA's expanded access program : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Collection:
Health Policy and Services Research
Contributor(s):
United States. Government Accountability Office, issuing body.
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health, issuing body.
Publication:
Washington, D.C. : U.S. Government Accountability Office, October 3, 2017
Language(s):
English
Format:
Text
Subject(s):
Drug Approval -- statistics & numerical data
Drugs, Investigational -- therapeutic use
Health Services Accessibility
Patient Safety
United States
United States. Food and Drug Administration
Genre(s):
Technical Report
Copyright:
The National Library of Medicine believes this item to be in the public domain. (More information)
Extent:
1 online resource (1 PDF file (5 pages))
NLM Unique ID:
101727255 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/101727255